Arming Vδ2 T cells with chimeric antigen receptors to combat cancer - Archive ouverte HAL
Article Dans Une Revue Clinical Cancer Research Année : 2024

Arming Vδ2 T cells with chimeric antigen receptors to combat cancer

Résumé

Immunotherapy has emerged as a promising approach in the field of cancer treatment, with chimeric antigen receptor (CAR) T cell therapy demonstrating remarkable success. However, challenges such as tumor antigen heterogeneity, immune evasion, and limited persistence of CAR-T cells have prompted the exploration of alternative cell types for CAR-based strategies. Gamma delta T cells, a unique subset of lymphocytes with inherent tumor recognition capabilities and versatile immune functions, have garnered increasing attention in recent years. In this review, we will present how arming Vδ2-T cells might be the basis for next-generation immunotherapies against solid tumors. Following a comprehensive overview of γδ T cell biology and innovative CAR engineering strategies, we will discuss the clinical potential of Vδ2 CAR-T cells to overcome the current limitations of immunotherapy in solid tumors. Indeed, while applications of Vδ2 CAR-T cells in cancer research are relatively in their infancy and many challenges are yet to be identified, Vδ2 CAR-T cells represent a promising breakthrough in cancer immunotherapy.
Fichier principal
Vignette du fichier
Thomas_ccr-23-3495.pdf (1.93 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04615675 , version 1 (18-06-2024)

Identifiants

Citer

Pauline Thomas, Pierre Paris, Claire Pecqueur. Arming Vδ2 T cells with chimeric antigen receptors to combat cancer. Clinical Cancer Research, In press, Online ahead of print. ⟨10.1158/1078-0432.CCR-23-3495⟩. ⟨hal-04615675⟩
38 Consultations
15 Téléchargements

Altmetric

Partager

More